Innate Pharma and MedImmune Test their Cancer Combo in the Clinic

By Super UserFebruary 5, 2018No Comments

Innate Pharma and MedImmune will test the combination of Innate’s cancer antibody and the checkpoint inhibitor durvalumab in patients with solid tumors.

{iframe}https://labiotech.eu/cancer-antibodies-innate-medimmune/{/iframe}

Tweet Share

About BioHealth Innovation

BioHealth Innovation, Inc. (BHI) is an innovation intermediary that translates market-relevant research into commercial success by connecting management, funding, and markets.

Learn More »

Contact

1 Church Street, Suite 801
Rockville, MD 20850
Email

Connect

Close Menu

SUBSCRIBE
Current Newsletter
About
Programs
Careers
- Regional Careers in BioHealth
BioTalk with Rich Bendis
BioTalk with Rich Bendis
News
BHI Newsletter Archives
Events

BioHealth
BHCR Incentives
Contact
Search

Search

When autocomplete results are available use up and down arrows to review and enter to go to the desired page. Touch device users, explore by touch or with swipe gestures.

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.